Microwave zaps prostate tumors with 3D precision

NCT ID NCT04582656

Completed Disease control Sponsor: Koelis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new way to treat intermediate-risk prostate cancer using a 3D map to guide microwaves directly to the main tumor. 76 men across Europe received the treatment, and researchers checked if the cancer was gone after 12 months. The goal is to destroy the cancer while avoiding damage to healthy tissue, potentially reducing side effects like incontinence and impotence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: microwave ablation (device)
What this could lead to: If successful, this could offer a less invasive treatment option for intermediate-risk prostate cancer, potentially reducing side effects compared to surgery or radiation.
What could go wrong: This is a small, single-arm study with only 76 participants and no comparison group. The long-term effectiveness and safety beyond 12 months are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

American Hospital of Paris

Neuilly-sur-Seine, 92200, France
Centre Hospitalier Universitaire de Bordeaux

Bordeaux, 33000, France
Hôpital Cochin (Assistance Publique - Hôpitaux de Paris)

Paris, 75014, France
Institut Jules Bordet

Brussels, 1000, Belgium
Urologie Nantes Clinique & Institut d'Urologie - Site Atlantis

Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.